Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 46
Filter
1.
J Clin Neurosci ; 71: 293-295, 2020 Jan.
Article in English | MEDLINE | ID: mdl-31548089

ABSTRACT

INTRODUCTION: Diffuse midline glioma is a newly WHO defined entity (grade IV) (Louis et al., 2016) which includes diffuse intrinsic pontine glioma (DIPG) reported in pediatric population and, occasionally, in young adults. Here, we present a detailed description of an atypical case of diffuse midline glioma in a 53 years old woman. CASE REPORT: A caucasian woman aged 53 from Ukraine, was referred to another neurological department complaining of 3 months history of progressive postural instability and gait impairment with frequent falling. Magnetic resonance demonstrated two brainstem lesions, hyperintense in FLAIR with "patchy" peripheral enhancement, leptomeningeal and cranial nerves enhancement. CSF was normal. Due to positive antinuclear antibodies test (ANA 1:360), intravenous steroid treatment was administered and reported to initially improve the patient condition. However, the following weeks the lady worsened. Imaging features were unchanged. Because quantiferon test resulted positive, MRI-Spectroscopy showed an inflammatory pattern and MRI perfusion study and brain FDG-PET, were normal, tubercolar granulomatous hypothesis was initially favored. Antitubercular therapy with isoniazid, pyrazinamide, ethambutol and rifampicin was started without any clinical improvement. Hence, the biopsy was proposed. The procedure revealed a diffuse midline pontine glioma. Considering the advanced stage of the disease, radiotherapy was not indicated. Patient died after eight months from the onset of neurological disturbances. CONCLUSION: Our case shows that diffuse midline glioma is a CNS tumor not limited to young population but occurring also in middle aged patients with an insidious pattern. We therefore recommend to perform biopsy at very early stages in patients with atypical brainstem lesions.


Subject(s)
Brain Stem Neoplasms/diagnosis , Brain Stem Neoplasms/pathology , Glioma/diagnosis , Glioma/pathology , Pons/pathology , Female , Humans , Middle Aged
2.
Neurol Sci ; 38(9): 1671-1676, 2017 Sep.
Article in English | MEDLINE | ID: mdl-28667365

ABSTRACT

Timely treatment is essential in acute ischemic stroke as the chances of recovery diminish over time, so efforts are necessary to streamline in-hospital pathways and reduce delays. Here, we analyse the interventions to reduce door-to-needle time in stroke patients suitable for intravenous thrombolysis at the Emergency Department of San Carlo Borromeo Hospital, Milan, Italy. All stroke patients consecutively treated with intravenous thrombolysis at our centre from January 1, 2013 to December 31, 2015 were included in this analysis. The main interventions adopted were (1) continuous education of personnel, (2) reconsideration of blood tests and identify the ones really affecting treatment decision, (3) approval of a new high-urgency Stroke Code activated as soon as the triage nurse comes to know of a potential thrombolysis candidate. Median door-to-needle time progressively decreased from 103 min (iqr 78-120) in 2013, to 92 min (iqr 72-112) in 2014, and to 37 min (iqr 27-58) with the new Stroke Code (p < 0.001) in 2015. Simultaneously, median onset-to-treatment time decreased from 177 min (iqr 142-188) in 2013, to 155 min (iqr 141-198) in 2014, and to 114 min (iqr 86-160) with the new Stroke Code (p < 0.001 and p 0.005, respectively). We did not observe any significant difference in bleeding risks or deaths, whereas the likelihood of favourable outcome (mRS 0-2) increased. Streamlining in-hospital pathways with progressive interventions significantly decreases door-to-needle time and onset-to-treatment time and may contribute to improve stroke outcomes.


Subject(s)
Brain Ischemia/therapy , Emergency Medical Services/methods , Stroke/therapy , Thrombolytic Therapy , Time-to-Treatment , Triage , Aged , Brain Ischemia/blood , Brain Ischemia/diagnostic imaging , Health Personnel/education , Humans , Prospective Studies , Quality Improvement , Stroke/blood , Stroke/diagnostic imaging , Triage/methods
3.
Neurol Sci ; 38(Suppl 1): 7-10, 2017 May.
Article in English | MEDLINE | ID: mdl-28527065

ABSTRACT

A few clinic-based magnetic resonance imaging studies report an increased risk of signal abnormalities in migraineurs brain's white matter, especially in migraine with aura subjects. A vascular genesis has been hypnotized and migraine with aura was considered an independent risk factor for stroke. Available data of magnetic resonance imaging alterations are often nonspecific and sometimes controversial. The aim of our study is to investigate migraine with aura patients with standardized brain magnetic resonance imaging to detect and to quantify the presence of white matter lesions and to analyze their relation with clinical data. We report preliminary data about first 90 subjects. We did not recognize any clinical aspect in close relationship with these alterations. The only clinical feature that seems to play a role in the presence of alterations is the age, and only in migraineurs women.


Subject(s)
Magnetic Resonance Imaging , Migraine with Aura/diagnostic imaging , White Matter/diagnostic imaging , Adolescent , Adult , Female , Humans , Magnetic Resonance Imaging/methods , Male , Middle Aged , Statistics as Topic/methods , Young Adult
4.
Lupus ; 22(10): 1064-9, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23918923

ABSTRACT

Aicardi-Goutières syndrome (AGS) is a rare genetic encephalopathy characterized by neurological and extraneurological involvement. A clinical overlap between AGS and systemic lupus erythematosus (SLE) has been reported. We describe an AGS patient who developed autoimmune manifestations: thyroiditis, cANCA positivity, antiphospholipid antibodies and cerebral ischemia. This first description of antiphospholipid syndrome in a TREX1-mutated patient further expands the clinical spectrum of AGS. Although the clinical overlap with SLE may indicate common pathogenic mechanisms, the autoimmune manifestations in AGS are so extensive that we suggest they should be considered a clinical feature of the disease, rather than a sign of coexistent SLE.


Subject(s)
Autoimmune Diseases of the Nervous System/immunology , Exodeoxyribonucleases/genetics , Immune System/physiology , Mutation , Nervous System Malformations/immunology , Phosphoproteins/genetics , Autoimmune Diseases of the Nervous System/genetics , Child, Preschool , Humans , Lupus Erythematosus, Systemic/immunology , Male , Nervous System Malformations/genetics
5.
Mutat Res ; 717(1-2): 99-108, 2011 Dec 01.
Article in English | MEDLINE | ID: mdl-21524657

ABSTRACT

Intracellular RNAses are involved in various functions, including microRNA maturation and turnover. Mutations occurring in genes encoding RNAses cause Aicardi-Goutiéres syndrome (AGS). AGS mutations silence RNAse activity, thus inducing accumulation of endogenous RNAs, mainly consisting of short RNAs and microRNAs. Overload of intracellular RNA triggers Toll like receptor-dependent interferon-alpha production in the brain, which in turn activates neurotoxic lymphocytes and inhibits angiogenesis thus inducing the typical clinical phenotype of AGS. However, these pathogenic mechanisms are attenuated after three years of age by the endogenous production of DNAJP58IPK and Cystatin F, which arrest AGS progression. Because RNAses are involved in microRNA turnover, we evaluated the expression of 957 microRNAs in lymphocytes from AGS patients and control patients. Our results indicate that microRNA overload occurs in AGS patients. This upregulation inhibits microRNA turnover impeding the synthesis of the novel microRNAs required for the differentiation and myelination of the brain during the initial period of postnatal life. These pathogenic mechanisms result in AGS, a neurological syndrome characterized by irritability, mild hyperpyrexia, pyramidal and extrapyramidal signs, and spastic-dystonic tetraplegia. Typical cerebrospinal fluid alterations include lymphocytosis and elevated interferon-alpha levels. Brain imaging demonstrates cerebral calcifications, white matter abnormalities, and progressive cerebral atrophy.Thus, evidence exists that mutations silencing intracellular RNases affect microRNA turnover resulting in the severe clinical consequences in the brain characterizing the clinical feature of AGS.


Subject(s)
Autoimmune Diseases of the Nervous System/enzymology , Autoimmune Diseases of the Nervous System/genetics , Isoenzymes/deficiency , MicroRNAs/metabolism , Nervous System Malformations/enzymology , Nervous System Malformations/genetics , Ribonucleases/deficiency , Animals , Autoimmune Diseases of the Nervous System/pathology , Autoimmune Diseases of the Nervous System/physiopathology , Child , DNA/metabolism , Female , Humans , Isoenzymes/chemistry , Isoenzymes/genetics , Male , Models, Molecular , Nervous System Malformations/pathology , Nervous System Malformations/physiopathology , Protein Structure, Tertiary , RNA/metabolism , Ribonucleases/chemistry , Ribonucleases/genetics
6.
Neurology ; 75(10): 898-903, 2010 Sep 07.
Article in English | MEDLINE | ID: mdl-20820001

ABSTRACT

BACKGROUND: Cognitive impairment has been reported in a significant proportion of patients with congenital muscular dystrophies (CMD), generally associated with brain changes. OBJECTIVES: The aim of this study was to establish 1) the overall prevalence of CMD and cognitive impairment in the Italian population; 2) the frequency of individual genetically defined forms; and 3) the presence of distinct phenotypes not associated with mutations in the known genes. METHODS: We included all patients with CMD and cognitive impairment followed in all the Italian tertiary neuromuscular centers. Clinical, brain MRI, and morphologic data were collected. Genetic screening of the known genes was performed according to clinical and muscle biopsy findings. RESULTS: Ninety-two of the 160 (58%) patients with CMD followed in our centers had cognitive impairment. alpha-Dystroglycan (alpha-DG) reduction on muscle biopsy was found in 73/92 (79%), with 42/73 carrying mutations in the known genes. Another 6/92 (7%) showed a laminin alpha2 deficiency on muscle biopsy and 5 of the 6 carried mutations in LAMA2. The remaining 13/92 (14%) patients had normal alpha-DG and laminin alpha2 expression on muscle. CONCLUSIONS: This is the first population study establishing the prevalence of CMD and cognitive impairment and providing a classification on the basis of clinical, MRI, and genetic findings. We also showed that cognitive impairment was not always associated with alpha-DG or laminin alpha2 reduction or with structural brain changes.


Subject(s)
Brain/pathology , Cognition Disorders/epidemiology , Muscular Dystrophies/congenital , Muscular Dystrophies/epidemiology , Brain Mapping , Cognition Disorders/genetics , Cognition Disorders/pathology , Comorbidity , Dystroglycans/genetics , Female , Genetic Predisposition to Disease , Genotype , Humans , Image Processing, Computer-Assisted , Italy/epidemiology , Laminin/genetics , Magnetic Resonance Imaging , Male , Muscle, Skeletal/pathology , Muscular Dystrophies/genetics , Muscular Dystrophies/pathology , Mutation , Phenotype , Prevalence
7.
AJNR Am J Neuroradiol ; 30(10): 1971-6, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19628626

ABSTRACT

BACKGROUND AND PURPOSE: To date, few studies have focused specifically on imaging findings in Aicardi-Goutières syndrome (AGS). We set out to evaluate retrospectively neuroradiologic data from a large sample of patients with AGS, focusing on the pattern of white matter abnormalities and the temporal evolution of the cerebral involvement to establish the radiologic natural history of the disease. MATERIALS AND METHODS: Thirty-six patients, 18 girls and 18 boys, were included. All had a clinical diagnosis of AGS, genetically confirmed in 31 of them. For every subject, we reviewed at least 1 CT and 1 MR imaging study; 19 (52.7%) had multiple examinations. In all, we reviewed 109 examinations. Clinical-neuroradiologic comparisons were analyzed by using the chi(2) test. RESULTS: Calcifications were found in all subjects, mainly in the basal ganglia, lobar white matter, and dentate nuclei. Abnormal white matter was present in all the subjects, showing 2 patterns of distribution: diffuse in 18 (50%) and an anteroposterior gradient in 18 (50%). Cystic areas were observed in the temporal and/or frontal lobes in 12/36 patients (33.3%). A correlation was found between early age at onset and severity of the leukoencephalopathy in the frontal (P = .024) and temporal (P = .034) regions. A significant degree of cerebral atrophy was found in 31/36 subjects (86.1%). The neuroradiologic presentation remained substantially stable with time. CONCLUSIONS: The different neuroradiologic presentations of AGS are here outlined for the first time in a large sample of patients. These findings may facilitate more precise and earlier diagnosis of this rare but probably underdiagnosed syndrome.


Subject(s)
Basal Ganglia Diseases/diagnostic imaging , Calcinosis/diagnostic imaging , Cerebellar Nuclei/diagnostic imaging , Tomography, X-Ray Computed , Adolescent , Basal Ganglia Diseases/pathology , Calcinosis/pathology , Cerebellar Nuclei/pathology , Child , Child, Preschool , Early Diagnosis , Female , Follow-Up Studies , Humans , Infant , Infant, Newborn , Magnetic Resonance Imaging , Male , Microcephaly/diagnostic imaging , Microcephaly/pathology , Nerve Fibers, Myelinated/diagnostic imaging , Nerve Fibers, Myelinated/pathology , Retrospective Studies
8.
Neurology ; 72(21): 1802-9, 2009 May 26.
Article in English | MEDLINE | ID: mdl-19299310

ABSTRACT

BACKGROUND: Congenital muscular dystrophies (CMD) with reduced glycosylation of alpha-dystroglycan (alpha-DG) are a heterogeneous group of conditions associated with mutations in six genes encoding proven or putative glycosyltransferases. OBJECTIVES: The aim of the study was to establish the prevalence of mutations in the six genes in the Italian population and the spectrum of clinical and brain MRI findings. METHODS: As part of a multicentric study involving all the tertiary neuromuscular centers in Italy, FKRP, POMT1, POMT2, POMGnT1, fukutin, and LARGE were screened in 81 patients with CMD and alpha-DG reduction on muscle biopsy (n = 76) or with a phenotype suggestive of alpha-dystroglycanopathy but in whom a muscle biopsy was not available for alpha-DG immunostaining (n = 5). RESULTS: Homozygous and compound heterozygous mutations were detected in a total of 43/81 patients (53%), and included seven novel variants. Mutations in POMT1 were the most prevalent in our cohort (21%), followed by POMT2 (11%), POMGnT1 (10%), and FKRP (9%). One patient carried two heterozygous mutations in fukutin and one case harbored a new homozygous variant in LARGE. No clear-cut genotype-phenotype correlation could be observed with each gene, resulting in a wide spectrum of clinical phenotypes. The more severe phenotypes, however, appeared to be consistently associated with mutations predicted to result in a severe disruption of the respective genes. CONCLUSIONS: Our data broaden the clinical spectrum associated with mutations in glycosyltransferases and provide data on their prevalence in the Italian population.


Subject(s)
Dystroglycans/metabolism , Glycosyltransferases/genetics , Muscular Dystrophies/congenital , Muscular Dystrophies/genetics , Adolescent , Brain/pathology , Child , Child, Preschool , Cohort Studies , Dystroglycans/analysis , Female , Glycosylation , Humans , Infant , Italy , Magnetic Resonance Imaging , Mannosyltransferases/genetics , Membrane Proteins/genetics , Muscle, Skeletal/chemistry , Muscle, Skeletal/pathology , Muscular Dystrophies/metabolism , Muscular Dystrophies/pathology , Mutation , N-Acetylglucosaminyltransferases/genetics , Pentosyltransferases , Phenotype , Prevalence , Proteins/genetics
9.
Neuromuscul Disord ; 18(7): 565-71, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18513969

ABSTRACT

Mutations in POMT1 and POMT2 genes were originally identified in Walker-Warburg syndrome (WWS) and subsequently reported in patients with milder phenotypes characterised by mental retardation with or without brain abnormalities and without ocular malformations. As part of a multicentric Italian study we screened the POMT1 and POMT2 genes in 61 congenital muscular dystrophy (CMD) patients with alpha-dystroglycan reduction on muscle biopsy and/or clinical and radiological findings suggestive of the known forms of CMD with alpha-dystroglycan deficiency. The aim of the study was to establish how frequently mutations in POMT1 and POMT2 occur in CMD patients in the Italian population and to evaluate the spectrum of associated phenotypes. Thirteen patients showed mutations in POMT1 and five harboured mutations in POMT2, accounting for a total of 20 different mutations, eight of which were novel (two in POMT1 and six in POMT2). Normal brain MRI associated with mental retardation and microcephaly was the most frequent finding in patients with mutations in POMT1 (six out of 13), but was also found in a patient with POMT2 mutations. Predominant cerebellar hypoplasia was also frequent both in patients with POMT1 (three out of 13) and POMT2 (three out of 5) mutations. A MEB phenotype with frontal cortical dysplasia and pons abnormalities was found in two patients with POMT1 and in one with POMT2 mutations, while a WWS phenotype was only found in a case with mutations in POMT1. Mutations causing frameshifts and stop codons were responsible for the more severe phenotypes. Our results provide further evidence that, as previously reported for FKRP, the array of mutations in POMT1 and POMT2 is ample and the spectrum of associated phenotypes is wider than initially thought.


Subject(s)
Family Health , Mannosyltransferases/genetics , Muscular Dystrophies/genetics , Mutation , Adolescent , Adult , Brain Diseases/genetics , Brain Diseases/pathology , Child , Child, Preschool , DNA Mutational Analysis , Dystroglycans/metabolism , Female , Humans , Italy , Magnetic Resonance Imaging , Male , Muscle, Skeletal/metabolism , Muscle, Skeletal/pathology , Muscular Dystrophies/pathology , Phenotype
10.
Dev Med Child Neurol ; 50(4): 311-5, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18312600

ABSTRACT

Plasticity of visual systems after early brain damage has been extensively studied in animal models but poorly documented in children after visual pathway lesions. This report describes the visual recovery of a male child who had a bilateral occipital lobe infarction at the age of 2 years 6 months, 10 days after colon resection for Hirschsprung disease. In the acute phase he had severe visual impairment without visual response. Some weeks later he could perceive movement. Since then, progressive recovery of his visual acuity and oculomotor abilities has been accompanied by a progressive reduction of the visual field defect. At 6 years 8 months, visual recognition acuity was 10/10 in both eyes and neuro-ophthalmological examination was normal, except for persistence of the visual field defect in the upper hemifield and a selective impairment of higher visual functions (recognition of object presented in a hard-to-decode way [e.g. overlapping figures], or use of complex visuospatial skills). The functional recovery observed in this patient confirms the adaptive plasticity of developing visual systems after early brain lesions. It suggests that in humans, as in animal models, processes related to cerebral plasticity may take place years after a brain lesion has been sustained.


Subject(s)
Blindness/physiopathology , Infarction, Posterior Cerebral Artery/physiopathology , Magnetic Resonance Imaging , Neuronal Plasticity/physiology , Occipital Lobe/physiopathology , Postoperative Complications/physiopathology , Child , Child, Preschool , Colectomy , Dominance, Cerebral/physiology , Female , Follow-Up Studies , Hirschsprung Disease/surgery , Humans , Infarction, Posterior Cerebral Artery/complications , Infarction, Posterior Cerebral Artery/diagnosis , Male , Postoperative Complications/diagnosis , Psychomotor Performance/physiology , Recovery of Function/physiology , Remission, Spontaneous , Visual Acuity/physiology , Visual Fields/physiology
12.
Neurology ; 65(7): 1057-65, 2005 Oct 11.
Article in English | MEDLINE | ID: mdl-16217059

ABSTRACT

BACKGROUND: Acute disseminated encephalomyelitis (ADEM) refers to a monophasic acute multifocal inflammatory CNS disease. However, both relapsing and site-restricted variants, possibly associated with peripheral nervous system (PNS) involvement, are also observed, and a systematic classification is lacking. OBJECTIVE: To describe a cohort of postinfectious ADEM patients, to propose a classification based on clinical and instrumental features, and to identify subgroups of patients with different prognostic factors. METHODS: Inpatients of a Neurologic and Infectious Disease Clinic affected by postinfectious CNS syndrome consecutively admitted over 5 years were studied. RESULTS: Of 75 patients enrolled, 60 fulfilled criteria for ADEM after follow-up lasting from 24 months to 7 years. Based on lesion distribution, patients were classified as encephalitis (20%), myelitis (23.3%), encephalomyelitis (13.3%), encephalomyeloradiculoneuritis (26.7%), and myeloradiculoneuritis (16.7%). Thirty patients (50%) had a favorable outcome. Fifteen patients (25%) showed a relapsing course. Poor outcome was related with older age at onset, female gender, elevated CSF proteins, and spinal cord and PNS involvement. All but two patients received high-dose steroids as first-line treatment, with a positive response in 39 (67%). Ten of 19 nonresponders (53%) benefited from high-dose IV immunoglobulin; 9 of 10 had PNS involvement. The data were not controlled. CONCLUSIONS: A high prevalence of "atypical variants" was found in this series, with site-restricted damage or additional peripheral nervous system (PNS) involvement. Prognosis and response to steroids were generally good, except for some patient subgroups. In patients with PNS involvement and steroid failure, a favorable effect of IV immunoglobulin was observed.


Subject(s)
Central Nervous System/physiopathology , Encephalomyelitis, Acute Disseminated/classification , Encephalomyelitis, Acute Disseminated/diagnosis , Peripheral Nerves/physiopathology , Adult , Age Factors , Aged , Anti-Inflammatory Agents/therapeutic use , Brain/immunology , Brain/pathology , Brain/physiopathology , Central Nervous System/immunology , Central Nervous System/pathology , Cohort Studies , Encephalomyelitis, Acute Disseminated/physiopathology , Female , Follow-Up Studies , Humans , Immunoglobulins, Intravenous/therapeutic use , Male , Middle Aged , Peripheral Nerves/immunology , Peripheral Nerves/pathology , Prognosis , Prospective Studies , Recurrence , Sex Factors , Spinal Cord/immunology , Spinal Cord/pathology , Spinal Cord/physiopathology , Spinal Nerve Roots/immunology , Spinal Nerve Roots/pathology , Spinal Nerve Roots/physiopathology , Steroids/therapeutic use , Treatment Outcome
13.
Neurology ; 64(9): 1621-4, 2005 May 10.
Article in English | MEDLINE | ID: mdl-15883328

ABSTRACT

Described are the outcomes of 11 Italian patients with Aicardi-Goutières syndrome. Neurologic symptoms progressed in the first year of life and stabilized by the end of the second year in 10 patients. White matter abnormalities remained stable; cerebral atrophy was stable in four patients and progressive in two. Calcifications increased (in number and size) in two of six patients. Serial CSF and serum interferon-alpha measurements (three patients) showed reduced CSF interferon-alpha levels.


Subject(s)
Abnormalities, Multiple/physiopathology , Atrophy/physiopathology , Brain/physiopathology , Calcinosis/physiopathology , Epilepsy/physiopathology , Heredodegenerative Disorders, Nervous System/physiopathology , Abnormalities, Multiple/blood , Abnormalities, Multiple/cerebrospinal fluid , Atrophy/congenital , Atrophy/pathology , Biomarkers/blood , Biomarkers/cerebrospinal fluid , Brain/diagnostic imaging , Brain/pathology , Calcinosis/congenital , Calcinosis/pathology , Cerebrospinal Fluid/chemistry , Cerebrospinal Fluid/cytology , Child , Child, Preschool , Disease Progression , Female , Follow-Up Studies , Genes, Recessive , Heredodegenerative Disorders, Nervous System/blood , Heredodegenerative Disorders, Nervous System/cerebrospinal fluid , Humans , Infant , Infant, Newborn , Interferon-alpha/blood , Interferon-alpha/cerebrospinal fluid , Italy , Longitudinal Studies , Male , Nerve Fibers, Myelinated/pathology , Radiography , Rare Diseases , Skin Diseases/physiopathology , Syndrome
14.
J Intellect Disabil Res ; 48(Pt 7): 679-86, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15357688

ABSTRACT

BACKGROUND: The diagnosis of intellectual disability (ID) is highly dependent on a comprehensive personal and family medical history, a complete physical examination and a careful developmental assessment of the patient. Our study intended to: (1) classify the aetiology of mild and severe ID in an adult population of 140 Italian subjects; (2) evaluate the frequency of associated medical conditions; (3) evaluate the age of diagnosis in both groups; and (4) underline the importance of aetiological diagnosis for adult ID patients also. METHODS: The study involved 140 consecutive adult Italian ID inpatients and outpatients neurologically investigated at the Neurological Institute C. Mondino of Pavia Service for Mental Retardation. A total of 80 patients had mild ID (MID group) (39 females, 41 males), mean age 34 years (range 19-61 years), mean IQ = 64 (range 51-75), and 60 had severe ID (SID group) (32 females, 28 males), mean age 30 years (range 19-69 years). They underwent a complete diagnostic work-up that comprised prenatal, perinatal and postnatal history, physical examinations, laboratory investigations, genetic survey and neuroradiological investigations to determine the aetiology of ID and to evaluate the presence of associated medical conditions. RESULTS: ID aetiology was classified as prenatal in 34% of the MID and 28% of the SID group. Perinatal and postnatal events were found in 6% of the MID and in 5% of the SID group. Associated medical conditions were found in 97 patients (47% MID and 26% SID). A genetic diagnosis was possible in 6% of patients above 20 years of age and in 5% of patients above 40 years. A diagnosis of cerebral dysgenesis was possible in 5% of patients above 20 years and 4% of patients above 40 years. CONCLUSIONS: A long interval between the diagnosis of ID and the aetiological definition can be observed in a significant percentage (24%) of our population, leading to unfortunate consequences of late diagnosis: late onset of a specific therapeutic program, genetic counselling that is frequently no more useful, and ineffective prenatal diagnosis, leading to the birth of other affected subjects (for familiar ID).


Subject(s)
Intellectual Disability/diagnosis , Adult , Aged , Brain/abnormalities , Chromosome Aberrations , Disability Evaluation , Female , Humans , Intellectual Disability/genetics , Male , Middle Aged , Severity of Illness Index , Time Factors , Wechsler Scales
15.
Neurology ; 63(6): 1118-21, 2004 Sep 28.
Article in English | MEDLINE | ID: mdl-15452315

ABSTRACT

The authors report a girl with autosomal recessive congenital muscular dystrophy linked to chromosome 6 (MDC1A) who carries a homozygous out-of-frame deletion in exon 56 of the LAMA2 gene but has a mild phenotype. She is still ambulant at age 13 years, shows white matter abnormalities on MRI, and traces of laminin alpha2 in her muscle biopsy with one of three antibodies used. This patient suggests that modulating factors can be associated with a less severe clinical phenotype in MDC1A.


Subject(s)
Laminin/deficiency , Muscular Dystrophies/genetics , Sequence Deletion , Adolescent , Biopsy , Brain/pathology , Child , Chromosomes, Human, Pair 6/genetics , Exons/genetics , Female , Genes, Recessive , Homozygote , Humans , Intellectual Disability/genetics , Laminin/analysis , Laminin/genetics , Laminin/physiology , Magnetic Resonance Imaging , Muscle, Skeletal/chemistry , Muscle, Skeletal/pathology , Muscular Dystrophies/congenital , Sequence Analysis, DNA
16.
Neurol Sci ; 25 Suppl 4: S356-60, 2004 Nov.
Article in English | MEDLINE | ID: mdl-15727233

ABSTRACT

In the past few years, magnetic resonance imaging (MRI) has become increasingly relevant in the diagnosis of multiple sclerosis (MS). Yet, the specificity of MR is limited. Atypical forms of MS and other diseases of the central nervous system may show similar patterns in MR. We briefly discuss the MR findings of the main MS-like diseases. Correct differential diagnosis can be carried out by combining the MR findings with clinical and laboratory findings.


Subject(s)
Brain/pathology , Magnetic Resonance Imaging/methods , Multiple Sclerosis/diagnosis , Brain Mapping , Brain Neoplasms/pathology , Demyelinating Diseases/pathology , Diagnosis, Differential , Humans , Neurologic Examination , Sensitivity and Specificity , Vascular Diseases/pathology
17.
Acta Diabetol ; 40 Suppl 1: S290-2, 2003 Oct.
Article in English | MEDLINE | ID: mdl-14618496

ABSTRACT

Creatinine concentration in 24-h urine has been proposed as an indirect measure of body skeletal muscle mass (SMM). We attempted to correlate urinary creatinine levels with SMM in eight patients with Duchenne muscular dystrophy, a progressive disease in which the degree of muscle wasting parallels the rate of progression. Magnetic resonance imaging and a newly developed protocol for image analysis were used for the measurement of SMM. The patients ate a creatine-free diet for the week before urine collection. Creatinine was measured with an enzymatic-colorimetric method. Mean (+/-SD) SMM value was 5.4+/-2.5 kg and urine creatinine levels 205.8+/-96.4 mg/day. Daily urinary creatinine excretion did not correlate with SMM. The simple creatinine determination in urine cannot predict SMM in Duchenne muscular dystrophy.


Subject(s)
Creatinine/urine , Muscle, Skeletal/anatomy & histology , Muscular Dystrophy, Duchenne/physiopathology , Biomarkers/urine , Body Height , Body Weight , Child , Humans , Regression Analysis , Reproducibility of Results
18.
Neurol Sci ; 24 Suppl 1: S15-6, 2003 May.
Article in English | MEDLINE | ID: mdl-12774204

ABSTRACT

Stroke in young people is an unexpected event, whose causes are more heterogeneous than in the older population. Moreover, its diagnosis must exclude a large number of other diseases. Thereby, imaging plays an important role in the diagnostic approach of these patients. The aims of the neuroradiological work-up are to confirm that an acute ischemic lesion has occurred, to determine the location and the extent of the lesion, to verify the patency of major neck and intracranial arteries and to exclude eventual underling pathologies. In this sense, MRI offers the best sensitivity and spatial resolution. The more frequent causes of ischemic stroke in young people are considered and the correspondent characteristic imaging aspects are described.


Subject(s)
Stroke/diagnosis , Stroke/etiology , Adolescent , Arteriosclerosis/complications , Cerebrovascular Disorders/diagnosis , Child , Diagnosis, Differential , Humans , Magnetic Resonance Imaging , Tomography, Emission-Computed
19.
Eur J Clin Nutr ; 57(2): 273-8, 2003 Feb.
Article in English | MEDLINE | ID: mdl-12571659

ABSTRACT

OBJECTIVE: To investigate the relationship between resting energy expenditure (REE) and body composition in Duchenne Muscular Dystrophy (DMD). DESIGN: An observational study. SETTING: University Research Centre. SUBJECTS: Nine Duchenne children (age range 6-12 y), mean relative weight 128%, agreed to undergo the investigation and all of them completed the study; INTERVENTIONS: Assessment of body composition (total body fat and skeletal muscle mass) by magnetic resonance imaging and resting energy expenditure by indirect calorimetry. MAIN OUTCOME MEASURES: Fat mass (FM; kg and percentage weight), fat-free mass (FFM; kg and percentage weight), muscle mass (kg and percentage weight), resting energy expenditure (kJ/kg body weight and kJ/kg fat-free mass). RESULTS: : In Duchenne children fat mass averages 32% and total skeletal muscle mass 20% of body weight. Resting energy expenditure per kg of body weight falls within the normal range for children of the same age range, while when expressed per kg of FFM is significantly higher than reference values. No relationship was found between REE and total skeletal muscle mass. CONCLUSIONS: Our results do not demonstrate a low REE in DMD boys; on the contrary REE per kg of FFM is higher than normal, probably due to the altered FFM composition. We suggest that the development of obesity in DMD children is not primarily due to a low REE but to other causes such as a reduction in physical activity and or overfeeding.


Subject(s)
Body Composition/physiology , Energy Metabolism/physiology , Muscular Dystrophy, Duchenne/physiopathology , Calorimetry, Indirect , Child , Humans , Italy , Magnetic Resonance Imaging , Male , Muscular Dystrophy, Duchenne/pathology
20.
J Neurol ; 249(1): 100-4, 2002 Jan.
Article in English | MEDLINE | ID: mdl-11954856

ABSTRACT

Randomized Controlled Trials have not let established the best pharmacological management of Acute Disseminated Encephalomyelitis (ADEM). High dose steroids are usually employed with good results, but in a few cases the clinical outcome is poor. In other patients, particularly those affected by the site restricted ADEM variants (myelitis), the disease shows a recurrent course resembling that of Multiple Sclerosis. We present here five patients, 3 of them affected by classic disseminated encephalomyelitis and 2 by a post infectious myelitis, which showed a good response to intravenous immunoglobulin (IVIg) after steroid treatment failure. In our report high dose steroids administration was substantially uneffective in all but one case, who showed a good response only during the first episode. On the contrary IVIg injection (0,4 gr/kg/day) produced a marked functional improvement in all patients starting within the first five days of drug administration and reaching a maximum within three weeks. One patient experienced a good effect nothwithstanding a steady dysability. In all cases, clinical evidence was supported by MRI controls showing improving posttreatment changes.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Drug Resistance/physiology , Encephalomyelitis, Acute Disseminated/drug therapy , Encephalomyelitis, Acute Disseminated/immunology , Immunoglobulins, Intravenous/therapeutic use , Aged , Disability Evaluation , Dose-Response Relationship, Drug , Encephalomyelitis, Acute Disseminated/physiopathology , Female , Humans , Male , Middle Aged , Steroids , Treatment Failure , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...